Insulet Corporation (PODD) 10-Year Financial Performance & Capital Metrics

PODD • • Industrial / General

HealthcareMedical DevicesDiabetes & Metabolic DevicesContinuous Glucose Monitoring

AboutInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Show more

Revenue $2.07B +22.1%
EBITDA $390M +33.1%
Net Income $418M +102.8%
EPS (Diluted) 5.78 +96.6%
Gross Margin 69.79% +2.1%
EBITDA Margin 18.81% +9.0%
Operating Margin 14.91% +15.0%
Net Margin 20.19% +66.1%
ROE 43.03% +26.1%
ROIC 14.43% +23.1%
Debt/Equity 1.17 -40.6%
Interest Coverage 7.23 +19.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 26.0%
✓Strong 5Y profit CAGR of 104.8%
✓Strong Piotroski F-Score: 8/9
✓Strong 5Y sales CAGR of 22.9%

✗Weaknesses

✗Expensive at 17.5x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y21.78%

5Y22.92%

3Y23.54%

TTM27.12%

Profit (Net Income) CAGR

10Y-

5Y104.84%

3Y192.01%

TTM-41.51%

EPS CAGR

10Y-

5Y97.99%

3Y184.88%

TTM-41.33%

ROCE

10Y Avg2.07%

5Y Avg7.45%

3Y Avg8.71%

Latest13.15%

Peer Comparison

Continuous Glucose Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PODDInsulet Corporation	20.15B	286.49	49.57	22.07%	9.76%	17.79%	1.52%	1.17
DXCMDexCom, Inc.	27B	69.24	48.76	11.34%	15.96%	26.44%	2.34%	1.23
AHCOAdaptHealth Corp.	1.44B	10.64	17.44	1.9%	2.81%	4.93%	16.36%	1.35
MODDModular Medical, Inc.	36.82M	0.47	-0.93			-276.23%		0.05
SENSSenseonics Holdings, Inc.	297.04M	7.27	-2.91	0.37%	-209.21%	-82.83%
TNDMTandem Diabetes Care, Inc.	1.43B	21.07	-14.33	25.74%	-20.2%	-152.95%	0.35%	1.80

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	263.89M	366.99M	463.77M	563.82M	738.2M	904.4M	1.1B	1.31B	1.7B	2.07B
Revenue Growth %	-0.09%	0.39%	0.26%	0.22%	0.31%	0.23%	0.21%	0.19%	0.3%	0.22%
Cost of Goods Sold+	130.62M	155.9M	186.6M	193.66M	257.9M	322.1M	346.7M	499.7M	537.2M	625.9M
COGS % of Revenue	0.49%	0.42%	0.4%	0.34%	0.35%	0.36%	0.32%	0.38%	0.32%	0.3%
Gross Profit+	133.27M	211.09M	277.17M	370.17M	480.3M	582.3M	752.1M	805.6M	1.16B	1.45B
Gross Margin %	0.51%	0.58%	0.6%	0.66%	0.65%	0.64%	0.68%	0.62%	0.68%	0.7%
Gross Profit Growth %	-0.07%	0.58%	0.31%	0.34%	0.3%	0.21%	0.29%	0.07%	0.44%	0.25%
Operating Expenses+	182.01M	221.79M	284.6M	342.8M	430.3M	530.8M	626.1M	768M	939.9M	1.14B
OpEx % of Revenue	0.69%	0.6%	0.61%	0.61%	0.58%	0.59%	0.57%	0.59%	0.55%	0.55%
Selling, General & Admin	138.8M	166.08M	208.9M	248M	298M	384M	466M	587.8M	734.9M	917.2M
SG&A % of Revenue	0.53%	0.45%	0.45%	0.44%	0.4%	0.42%	0.42%	0.45%	0.43%	0.44%
Research & Development	43.21M	55.71M	74.45M	88.61M	132.3M	146.8M	160.1M	180.2M	205M	219.6M
R&D % of Revenue	0.16%	0.15%	0.16%	0.16%	0.18%	0.16%	0.15%	0.14%	0.12%	0.11%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-48.74M	-10.7M	-7.4M	27.4M	50M	51.5M	126M	37.6M	220M	308.9M
Operating Margin %	-0.18%	-0.03%	-0.02%	0.05%	0.07%	0.06%	0.11%	0.03%	0.13%	0.15%
Operating Income Growth %	-4.49%	0.78%	0.31%	4.7%	0.82%	0.03%	1.45%	-0.7%	4.85%	0.4%
EBITDA+	-32.9M	3.13M	6.5M	43M	77.9M	106.9M	183.4M	100.8M	292.8M	389.7M
EBITDA Margin %	-0.12%	0.01%	0.01%	0.08%	0.11%	0.12%	0.17%	0.08%	0.17%	0.19%
EBITDA Growth %	-10.82%	1.1%	1.08%	5.62%	0.81%	0.37%	0.72%	-0.45%	1.9%	0.33%
D&A (Non-Cash Add-back)	15.84M	13.83M	13.9M	15.6M	27.9M	55.4M	57.4M	63.2M	72.8M	80.8M
EBIT	-48.68M	-12.43M	-7.5M	31.5M	46.3M	54.9M	82.2M	45.8M	250.8M	342.9M
Net Interest Income+	-12.65M	-13.56M	-18.6M	-21.3M	-34.6M	-45.1M	-61.2M	-26.7M	-7.6M	-3.2M
Interest Income	58K	825K	2.63M	6.71M	0	3M	500K	9.3M	28.6M	39.5M
Interest Expense	12.71M	14.39M	19.19M	22.2M	34.6M	48.1M	61.7M	36M	36.2M	42.7M
Other Income/Expense	-12.65M	-16.11M	-19.2M	-22.2M	-35.5M	-41.8M	-105.5M	-27.8M	-5.4M	-8.7M
Pretax Income+	-61.39M	-26.82M	-26.6M	5.2M	14.5M	9.7M	20.5M	9.8M	214.6M	300.2M
Pretax Margin %	-0.23%	-0.07%	-0.06%	0.01%	0.02%	0.01%	0.02%	0.01%	0.13%	0.14%
Income Tax+	212K	392K	200K	1.9M	2.9M	2.9M	3.7M	5.2M	8.3M	-118.1M
Effective Tax Rate %	1.2%	1.08%	1.01%	0.63%	0.8%	0.7%	0.82%	0.47%	0.96%	1.39%
Net Income+	-73.52M	-28.88M	-26.83M	3.29M	11.6M	6.8M	16.8M	4.6M	206.3M	418.3M
Net Margin %	-0.28%	-0.08%	-0.06%	0.01%	0.02%	0.01%	0.02%	0%	0.12%	0.2%
Net Income Growth %	-0.43%	0.61%	0.07%	1.12%	2.52%	-0.41%	1.47%	-0.73%	43.85%	1.03%
Net Income (Continuing)	-61.6M	-27.21M	-26.8M	3.3M	11.6M	6.8M	16.8M	4.6M	206.3M	418.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.29	-0.50	-0.46	0.05	0.19	0.10	0.25	0.07	2.94	5.78
EPS Growth %	-0.39%	0.61%	0.08%	1.12%	2.52%	-0.47%	1.5%	-0.74%	43.68%	0.97%
EPS (Basic)	-1.29	-0.51	-0.46	0.06	0.19	0.11	0.25	0.07	2.96	5.97
Diluted Shares Outstanding	56.79M	57.25M	58M	61.01M	62.3M	65.95M	68.58M	69.91M	73.63M	73.89M
Basic Shares Outstanding	56.79M	56.69M	58M	58.86M	60.59M	64.73M	67.7M	69.38M	69.75M	70.08M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	190.76M	369.96M	537.17M	454.01M	581.5M	1.24B	1.32B	1.3B	1.57B	1.87B
Cash & Short-Term Investments	122.67M	298.57M	440.06M	288.95M	376.1M	947.6M	791.6M	674.7M	704.2M	953.4M
Cash Only	122.67M	137.17M	272.58M	113.91M	203.7M	907.2M	791.6M	623.9M	650.7M	953.4M
Short-Term Investments	0	161.4M	167.48M	175.04M	172.4M	40.4M	0	50.8M	53.5M	0
Accounts Receivable	42.53M	28.8M	53.37M	76.67M	82.8M	83.8M	161M	205.6M	359.7M	365.5M
Days Sales Outstanding	58.82	28.65	42.01	49.63	40.94	33.82	53.48	57.49	77.36	64.4
Inventory	12.02M	35.51M	33.79M	71.41M	101M	154.3M	303.2M	346.8M	402.6M	430.4M
Days Inventory Outstanding	33.6	83.15	66.1	134.6	142.94	174.85	319.2	253.32	273.55	250.99
Other Current Assets	13.54M	7.07M	9.95M	16.98M	21.6M	52M	60.7M	71.7M	99.8M	121.9M
Total Non-Current Assets+	84.36M	86.69M	279.57M	474.74M	561.4M	635.2M	732.3M	952.3M	1.02B	1.22B
Property, Plant & Equipment	41.79M	46.27M	107.86M	258.38M	415.5M	493.6M	546.4M	625.9M	692.8M	759.8M
Fixed Asset Turnover	6.31x	7.93x	4.30x	2.18x	1.78x	1.83x	2.01x	2.09x	2.45x	2.73x
Goodwill	39.61M	39.68M	39.84M	39.65M	39.8M	39.8M	39.8M	51.7M	51.7M	51.5M
Intangible Assets	933K	528K	4.35M	10.38M	13.2M	28.7M	36.6M	75.5M	98.7M	98.5M
Long-Term Investments	0	0	125.55M	140.78M	58.4M	14.8M	19.3M	15M	0	5.5M
Other Non-Current Assets	2.03M	216K	1.97M	25.54M	34.5M	58.3M	90.2M	184.2M	178.7M	159.4M
Total Assets+	275.13M	456.65M	816.74M	928.74M	1.14B	1.87B	2.05B	2.25B	2.59B	3.09B
Asset Turnover	0.96x	0.80x	0.57x	0.61x	0.65x	0.48x	0.54x	0.58x	0.66x	0.67x
Asset Growth %	-0.09%	0.66%	0.79%	0.14%	0.23%	0.64%	0.09%	0.1%	0.15%	0.19%
Total Current Liabilities+	65.16M	55.7M	86.03M	115.66M	157.7M	207.8M	228.8M	364.7M	451.2M	528.4M
Accounts Payable	15.21M	13.16M	24.41M	25.5M	54.5M	54.1M	37.7M	30.8M	19.2M	19.8M
Days Payables Outstanding	42.51	30.81	47.75	48.06	77.13	61.31	39.69	22.5	13.05	11.55
Short-Term Debt	5.52M	269K	0	0	3.6M	20.5M	30.1M	31.1M	52.9M	85.9M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	25.21M	18.96M	24.31M	51.15M	50.6M	74.7M	87.2M	190.8M	241.7M	267.9M
Current Ratio	2.93x	6.64x	6.24x	3.93x	3.69x	5.96x	5.75x	3.56x	3.47x	3.54x
Quick Ratio	2.74x	6.00x	5.85x	3.31x	3.05x	5.21x	4.43x	2.61x	2.58x	2.73x
Cash Conversion Cycle	49.91	80.98	60.35	136.17	106.75	147.37	333	288.31	337.86	303.84
Total Non-Current Liabilities+	175.92M	337.8M	572.2M	600.99M	909.3M	1.06B	1.26B	1.41B	1.4B	1.35B
Long-Term Debt	171.97M	332.77M	566.17M	591.98M	887.9M	1.04B	1.25B	1.37B	1.37B	1.3B
Capital Lease Obligations	269K	0	0	0	14.4M	12M	7.6M	27.4M	29.5M	40M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.75M	5.03M	5.13M	8.11M	6M	4.8M	5.8M	6.7M	6.5M	9.6M
Total Liabilities	241.07M	393.5M	658.23M	716.64M	1.07B	1.27B	1.49B	1.77B	1.86B	1.88B
Total Debt+	177.49M	333.04M	566.17M	591.98M	905.9M	1.08B	1.29B	1.43B	1.45B	1.42B
Net Debt	54.81M	195.86M	293.6M	478.07M	702.2M	169M	494.9M	808.9M	798.1M	468.6M
Debt / Equity	5.21x	5.27x	3.57x	2.79x	11.94x	1.78x	2.31x	3.01x	1.98x	1.17x
Debt / EBITDA	-	106.44x	87.10x	13.77x	11.63x	10.07x	7.01x	14.21x	4.95x	3.65x
Net Debt / EBITDA	-	62.60x	45.17x	11.12x	9.01x	1.58x	2.70x	8.02x	2.73x	1.20x
Interest Coverage	-3.83x	-0.74x	-0.39x	1.23x	1.45x	1.07x	2.04x	1.04x	6.08x	7.23x
Total Equity+	34.05M	63.15M	158.52M	212.1M	75.9M	603.6M	556.3M	476.4M	732.7M	1.21B
Equity Growth %	-0.59%	0.85%	1.51%	0.34%	-0.64%	6.95%	-0.08%	-0.14%	0.54%	0.65%
Book Value per Share	0.60	1.10	2.73	3.48	1.22	9.15	8.11	6.81	9.95	16.40
Total Shareholders' Equity	34.05M	63.15M	158.52M	212.1M	75.9M	603.6M	556.3M	476.4M	732.7M	1.21B
Common Stock	57K	57K	58K	59K	100K	100K	100K	100K	100K	100K
Retained Earnings	-651.54M	-680.42M	-707.25M	-683.61M	-672M	-666.3M	-649.5M	-584.3M	-378M	40.3M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-654K	-726K	-493K	-2.9M	-1.2M	5.5M	-2.2M	20M	8M	-13.2M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.55M	15.91M	41.3M	35.9M	98.4M	84M	-68.1M	119M	145.7M	430.3M
Operating CF Margin %	-0.05%	0.04%	0.09%	0.06%	0.13%	0.09%	-0.06%	0.09%	0.09%	0.21%
Operating CF Growth %	-2.41%	2.27%	1.6%	-0.13%	1.74%	-0.15%	-1.81%	2.75%	0.22%	1.95%
Net Income	-73.52M	-28.88M	-26.8M	3.3M	11.6M	6.8M	16.8M	4.6M	206.3M	418.3M
Depreciation & Amortization	15.84M	13.83M	13.9M	15.6M	27.9M	55.4M	57.4M	63.2M	72.8M	80.8M
Stock-Based Compensation	19.18M	23.62M	31.9M	37.5M	28.7M	35.9M	34.4M	40.9M	48.3M	69.3M
Deferred Taxes	0	0	0	0	0	0	0	-1M	500K	-136.9M
Other Non-Cash Items	17.95M	20.92M	20.6M	32.3M	49.9M	49.3M	86.9M	13.8M	8.4M	15.8M
Working Capital Changes	8M	-13.58M	1.7M	-52.8M	-19.7M	-63.4M	-263.6M	-2.5M	-190.6M	-17M
Change in Receivables	-9.79M	12.55M	-26.3M	-14.6M	-10.9M	-13.7M	-71.3M	-51.8M	-154.2M	-10.4M
Change in Inventory	-722K	-24.1M	1.7M	-38.8M	-30.2M	-50.5M	-154.4M	-49.1M	-53.6M	-32.4M
Change in Payables	17.99M	639K	27.3M	-5.4M	25.6M	7.1M	-15.6M	-2.4M	-11M	2.2M
Cash from Investing+	-15.32M	-178.01M	-210.8M	-184.5M	-73.6M	14M	-82.7M	-191.1M	-119.4M	-146.2M
Capital Expenditures	-10.61M	-22.11M	-77.23M	-162.35M	0	-166.5M	-122.7M	-157.3M	-109.2M	-134M
CapEx % of Revenue	0.04%	0.06%	0.17%	0.29%	0.23%	0.18%	0.11%	0.12%	0.06%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	26K	-46K	-170.9M	0	0	0	0	0
Cash from Financing+	-371K	176.57M	304.5M	-8.7M	73.5M	605.5M	40.7M	-40.3M	-13.6M	-28.1M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.65M	-2.87M	-4.1M	-17.82M	-8.6M	-30.3M	-32.2M	-16.8M	-13.5M	-7.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.16M	-6.2M	-36.02M	-126.45M	-72.5M	-82.5M	-190.8M	-38.3M	70.1M	305.4M
FCF Margin %	-0.09%	-0.02%	-0.08%	-0.22%	-0.1%	-0.09%	-0.17%	-0.03%	0.04%	0.15%
FCF Growth %	-8.03%	0.73%	-4.81%	-2.51%	0.43%	-0.14%	-1.31%	0.8%	2.83%	3.36%
FCF per Share	-0.41	-0.11	-0.62	-2.07	-1.16	-1.25	-2.78	-0.55	0.95	4.13
FCF Conversion (FCF/Net Income)	0.17x	-0.55x	-1.54x	10.91x	8.48x	12.35x	-4.05x	25.87x	0.71x	1.03x
Interest Paid	4.03M	3.69M	2.5M	0	0	2.6M	21.5M	34.2M	49.9M	0
Taxes Paid	109K	932K	500K	800K	2.5M	3M	7M	5.5M	8.1M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-124.74%	-59.42%	-24.21%	1.78%	8.06%	2%	2.9%	0.89%	34.12%	43.03%
Return on Invested Capital (ROIC)	-37.27%	-4.62%	-1.56%	3.6%	5.11%	4.98%	10.36%	2.41%	11.72%	14.43%
Gross Margin	50.5%	57.52%	59.76%	65.65%	65.06%	64.39%	68.45%	61.72%	68.35%	69.79%
Net Margin	-27.86%	-7.87%	-5.79%	0.58%	1.57%	0.75%	1.53%	0.35%	12.16%	20.19%
Debt / Equity	5.21x	5.27x	3.57x	2.79x	11.94x	1.78x	2.31x	3.01x	1.98x	1.17x
Interest Coverage	-3.83x	-0.74x	-0.39x	1.23x	1.45x	1.07x	2.04x	1.04x	6.08x	7.23x
FCF Conversion	0.17x	-0.55x	-1.54x	10.91x	8.48x	12.35x	-4.05x	25.87x	0.71x	1.03x
Revenue Growth	-8.6%	39.07%	26.37%	21.57%	30.93%	22.51%	21.49%	18.79%	30.02%	22.07%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
International Omnipod	301.67M	391.55M	-	673.5M	834.9M	1.01B	1.25B	1.66B	2.03B
International Omnipod Growth	-	29.79%	-	-	23.96%	21.14%	23.37%	33.12%	22.37%
Drug Delivery	65.31M	72.22M	-	64.7M	69.5M	87.4M	57.5M	36M	38.9M
Drug Delivery Growth	-	10.57%	-	-	7.42%	25.76%	-34.21%	-37.39%	8.06%

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	295.1M	343.81M	391.8M	485.1M	596.4M	738.9M	942.3M	1.29B	1.55B
UNITED STATES Growth	-	16.51%	13.96%	23.81%	22.94%	23.89%	27.53%	36.58%	20.30%
Non-US	71.89M	119.95M	172.02M	253.1M	308M	359.9M	363M	410.1M	523.4M
Non-US Growth	-	66.86%	43.41%	47.13%	21.69%	16.85%	0.86%	12.98%	27.63%

Frequently Asked Questions

Valuation & Price

Insulet Corporation (PODD) has a price-to-earnings (P/E) ratio of 49.6x. This suggests investors expect higher future growth.

Growth & Financials

Insulet Corporation (PODD) reported $2.52B in revenue for fiscal year 2024. This represents a 1556% increase from $152.3M in 2011.

Insulet Corporation (PODD) grew revenue by 22.1% over the past year. This is strong growth.

Yes, Insulet Corporation (PODD) is profitable, generating $246.2M in net income for fiscal year 2024 (20.2% net margin).

Dividend & Returns

Insulet Corporation (PODD) has a return on equity (ROE) of 43.0%. This is excellent, indicating efficient use of shareholder capital.

Insulet Corporation (PODD) generated $421.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Insulet Corporation (PODD) 10-Year Financial Performance & Capital Metrics

PODD • • Industrial / General

HealthcareMedical DevicesDiabetes & Metabolic DevicesContinuous Glucose Monitoring

Revenue $2.07B +22.1%
EBITDA $390M +33.1%
Net Income $418M +102.8%
EPS (Diluted) 5.78 +96.6%
Gross Margin 69.79% +2.1%
EBITDA Margin 18.81% +9.0%
Operating Margin 14.91% +15.0%
Net Margin 20.19% +66.1%
ROE 43.03% +26.1%
ROIC 14.43% +23.1%
Debt/Equity 1.17 -40.6%
Interest Coverage 7.23 +19.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 26.0%
✓Strong 5Y profit CAGR of 104.8%
✓Strong Piotroski F-Score: 8/9
✓Strong 5Y sales CAGR of 22.9%

✗Weaknesses

✗Expensive at 17.5x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y21.78%

5Y22.92%

3Y23.54%

TTM27.12%

Profit (Net Income) CAGR

10Y-

5Y104.84%

3Y192.01%

TTM-41.51%

EPS CAGR

10Y-

5Y97.99%

3Y184.88%

TTM-41.33%

ROCE

10Y Avg2.07%

5Y Avg7.45%

3Y Avg8.71%

Latest13.15%

Peer Comparison

Continuous Glucose Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PODDInsulet Corporation	20.15B	286.49	49.57	22.07%	9.76%	17.79%	1.52%	1.17
DXCMDexCom, Inc.	27B	69.24	48.76	11.34%	15.96%	26.44%	2.34%	1.23
AHCOAdaptHealth Corp.	1.44B	10.64	17.44	1.9%	2.81%	4.93%	16.36%	1.35
MODDModular Medical, Inc.	36.82M	0.47	-0.93			-276.23%		0.05
SENSSenseonics Holdings, Inc.	297.04M	7.27	-2.91	0.37%	-209.21%	-82.83%
TNDMTandem Diabetes Care, Inc.	1.43B	21.07	-14.33	25.74%	-20.2%	-152.95%	0.35%	1.80

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	263.89M	366.99M	463.77M	563.82M	738.2M	904.4M	1.1B	1.31B	1.7B	2.07B
Revenue Growth %	-0.09%	0.39%	0.26%	0.22%	0.31%	0.23%	0.21%	0.19%	0.3%	0.22%
Cost of Goods Sold+	130.62M	155.9M	186.6M	193.66M	257.9M	322.1M	346.7M	499.7M	537.2M	625.9M
COGS % of Revenue	0.49%	0.42%	0.4%	0.34%	0.35%	0.36%	0.32%	0.38%	0.32%	0.3%
Gross Profit+	133.27M	211.09M	277.17M	370.17M	480.3M	582.3M	752.1M	805.6M	1.16B	1.45B
Gross Margin %	0.51%	0.58%	0.6%	0.66%	0.65%	0.64%	0.68%	0.62%	0.68%	0.7%
Gross Profit Growth %	-0.07%	0.58%	0.31%	0.34%	0.3%	0.21%	0.29%	0.07%	0.44%	0.25%
Operating Expenses+	182.01M	221.79M	284.6M	342.8M	430.3M	530.8M	626.1M	768M	939.9M	1.14B
OpEx % of Revenue	0.69%	0.6%	0.61%	0.61%	0.58%	0.59%	0.57%	0.59%	0.55%	0.55%
Selling, General & Admin	138.8M	166.08M	208.9M	248M	298M	384M	466M	587.8M	734.9M	917.2M
SG&A % of Revenue	0.53%	0.45%	0.45%	0.44%	0.4%	0.42%	0.42%	0.45%	0.43%	0.44%
Research & Development	43.21M	55.71M	74.45M	88.61M	132.3M	146.8M	160.1M	180.2M	205M	219.6M
R&D % of Revenue	0.16%	0.15%	0.16%	0.16%	0.18%	0.16%	0.15%	0.14%	0.12%	0.11%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-48.74M	-10.7M	-7.4M	27.4M	50M	51.5M	126M	37.6M	220M	308.9M
Operating Margin %	-0.18%	-0.03%	-0.02%	0.05%	0.07%	0.06%	0.11%	0.03%	0.13%	0.15%
Operating Income Growth %	-4.49%	0.78%	0.31%	4.7%	0.82%	0.03%	1.45%	-0.7%	4.85%	0.4%
EBITDA+	-32.9M	3.13M	6.5M	43M	77.9M	106.9M	183.4M	100.8M	292.8M	389.7M
EBITDA Margin %	-0.12%	0.01%	0.01%	0.08%	0.11%	0.12%	0.17%	0.08%	0.17%	0.19%
EBITDA Growth %	-10.82%	1.1%	1.08%	5.62%	0.81%	0.37%	0.72%	-0.45%	1.9%	0.33%
D&A (Non-Cash Add-back)	15.84M	13.83M	13.9M	15.6M	27.9M	55.4M	57.4M	63.2M	72.8M	80.8M
EBIT	-48.68M	-12.43M	-7.5M	31.5M	46.3M	54.9M	82.2M	45.8M	250.8M	342.9M
Net Interest Income+	-12.65M	-13.56M	-18.6M	-21.3M	-34.6M	-45.1M	-61.2M	-26.7M	-7.6M	-3.2M
Interest Income	58K	825K	2.63M	6.71M	0	3M	500K	9.3M	28.6M	39.5M
Interest Expense	12.71M	14.39M	19.19M	22.2M	34.6M	48.1M	61.7M	36M	36.2M	42.7M
Other Income/Expense	-12.65M	-16.11M	-19.2M	-22.2M	-35.5M	-41.8M	-105.5M	-27.8M	-5.4M	-8.7M
Pretax Income+	-61.39M	-26.82M	-26.6M	5.2M	14.5M	9.7M	20.5M	9.8M	214.6M	300.2M
Pretax Margin %	-0.23%	-0.07%	-0.06%	0.01%	0.02%	0.01%	0.02%	0.01%	0.13%	0.14%
Income Tax+	212K	392K	200K	1.9M	2.9M	2.9M	3.7M	5.2M	8.3M	-118.1M
Effective Tax Rate %	1.2%	1.08%	1.01%	0.63%	0.8%	0.7%	0.82%	0.47%	0.96%	1.39%
Net Income+	-73.52M	-28.88M	-26.83M	3.29M	11.6M	6.8M	16.8M	4.6M	206.3M	418.3M
Net Margin %	-0.28%	-0.08%	-0.06%	0.01%	0.02%	0.01%	0.02%	0%	0.12%	0.2%
Net Income Growth %	-0.43%	0.61%	0.07%	1.12%	2.52%	-0.41%	1.47%	-0.73%	43.85%	1.03%
Net Income (Continuing)	-61.6M	-27.21M	-26.8M	3.3M	11.6M	6.8M	16.8M	4.6M	206.3M	418.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.29	-0.50	-0.46	0.05	0.19	0.10	0.25	0.07	2.94	5.78
EPS Growth %	-0.39%	0.61%	0.08%	1.12%	2.52%	-0.47%	1.5%	-0.74%	43.68%	0.97%
EPS (Basic)	-1.29	-0.51	-0.46	0.06	0.19	0.11	0.25	0.07	2.96	5.97
Diluted Shares Outstanding	56.79M	57.25M	58M	61.01M	62.3M	65.95M	68.58M	69.91M	73.63M	73.89M
Basic Shares Outstanding	56.79M	56.69M	58M	58.86M	60.59M	64.73M	67.7M	69.38M	69.75M	70.08M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	190.76M	369.96M	537.17M	454.01M	581.5M	1.24B	1.32B	1.3B	1.57B	1.87B
Cash & Short-Term Investments	122.67M	298.57M	440.06M	288.95M	376.1M	947.6M	791.6M	674.7M	704.2M	953.4M
Cash Only	122.67M	137.17M	272.58M	113.91M	203.7M	907.2M	791.6M	623.9M	650.7M	953.4M
Short-Term Investments	0	161.4M	167.48M	175.04M	172.4M	40.4M	0	50.8M	53.5M	0
Accounts Receivable	42.53M	28.8M	53.37M	76.67M	82.8M	83.8M	161M	205.6M	359.7M	365.5M
Days Sales Outstanding	58.82	28.65	42.01	49.63	40.94	33.82	53.48	57.49	77.36	64.4
Inventory	12.02M	35.51M	33.79M	71.41M	101M	154.3M	303.2M	346.8M	402.6M	430.4M
Days Inventory Outstanding	33.6	83.15	66.1	134.6	142.94	174.85	319.2	253.32	273.55	250.99
Other Current Assets	13.54M	7.07M	9.95M	16.98M	21.6M	52M	60.7M	71.7M	99.8M	121.9M
Total Non-Current Assets+	84.36M	86.69M	279.57M	474.74M	561.4M	635.2M	732.3M	952.3M	1.02B	1.22B
Property, Plant & Equipment	41.79M	46.27M	107.86M	258.38M	415.5M	493.6M	546.4M	625.9M	692.8M	759.8M
Fixed Asset Turnover	6.31x	7.93x	4.30x	2.18x	1.78x	1.83x	2.01x	2.09x	2.45x	2.73x
Goodwill	39.61M	39.68M	39.84M	39.65M	39.8M	39.8M	39.8M	51.7M	51.7M	51.5M
Intangible Assets	933K	528K	4.35M	10.38M	13.2M	28.7M	36.6M	75.5M	98.7M	98.5M
Long-Term Investments	0	0	125.55M	140.78M	58.4M	14.8M	19.3M	15M	0	5.5M
Other Non-Current Assets	2.03M	216K	1.97M	25.54M	34.5M	58.3M	90.2M	184.2M	178.7M	159.4M
Total Assets+	275.13M	456.65M	816.74M	928.74M	1.14B	1.87B	2.05B	2.25B	2.59B	3.09B
Asset Turnover	0.96x	0.80x	0.57x	0.61x	0.65x	0.48x	0.54x	0.58x	0.66x	0.67x
Asset Growth %	-0.09%	0.66%	0.79%	0.14%	0.23%	0.64%	0.09%	0.1%	0.15%	0.19%
Total Current Liabilities+	65.16M	55.7M	86.03M	115.66M	157.7M	207.8M	228.8M	364.7M	451.2M	528.4M
Accounts Payable	15.21M	13.16M	24.41M	25.5M	54.5M	54.1M	37.7M	30.8M	19.2M	19.8M
Days Payables Outstanding	42.51	30.81	47.75	48.06	77.13	61.31	39.69	22.5	13.05	11.55
Short-Term Debt	5.52M	269K	0	0	3.6M	20.5M	30.1M	31.1M	52.9M	85.9M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	25.21M	18.96M	24.31M	51.15M	50.6M	74.7M	87.2M	190.8M	241.7M	267.9M
Current Ratio	2.93x	6.64x	6.24x	3.93x	3.69x	5.96x	5.75x	3.56x	3.47x	3.54x
Quick Ratio	2.74x	6.00x	5.85x	3.31x	3.05x	5.21x	4.43x	2.61x	2.58x	2.73x
Cash Conversion Cycle	49.91	80.98	60.35	136.17	106.75	147.37	333	288.31	337.86	303.84
Total Non-Current Liabilities+	175.92M	337.8M	572.2M	600.99M	909.3M	1.06B	1.26B	1.41B	1.4B	1.35B
Long-Term Debt	171.97M	332.77M	566.17M	591.98M	887.9M	1.04B	1.25B	1.37B	1.37B	1.3B
Capital Lease Obligations	269K	0	0	0	14.4M	12M	7.6M	27.4M	29.5M	40M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.75M	5.03M	5.13M	8.11M	6M	4.8M	5.8M	6.7M	6.5M	9.6M
Total Liabilities	241.07M	393.5M	658.23M	716.64M	1.07B	1.27B	1.49B	1.77B	1.86B	1.88B
Total Debt+	177.49M	333.04M	566.17M	591.98M	905.9M	1.08B	1.29B	1.43B	1.45B	1.42B
Net Debt	54.81M	195.86M	293.6M	478.07M	702.2M	169M	494.9M	808.9M	798.1M	468.6M
Debt / Equity	5.21x	5.27x	3.57x	2.79x	11.94x	1.78x	2.31x	3.01x	1.98x	1.17x
Debt / EBITDA	-	106.44x	87.10x	13.77x	11.63x	10.07x	7.01x	14.21x	4.95x	3.65x
Net Debt / EBITDA	-	62.60x	45.17x	11.12x	9.01x	1.58x	2.70x	8.02x	2.73x	1.20x
Interest Coverage	-3.83x	-0.74x	-0.39x	1.23x	1.45x	1.07x	2.04x	1.04x	6.08x	7.23x
Total Equity+	34.05M	63.15M	158.52M	212.1M	75.9M	603.6M	556.3M	476.4M	732.7M	1.21B
Equity Growth %	-0.59%	0.85%	1.51%	0.34%	-0.64%	6.95%	-0.08%	-0.14%	0.54%	0.65%
Book Value per Share	0.60	1.10	2.73	3.48	1.22	9.15	8.11	6.81	9.95	16.40
Total Shareholders' Equity	34.05M	63.15M	158.52M	212.1M	75.9M	603.6M	556.3M	476.4M	732.7M	1.21B
Common Stock	57K	57K	58K	59K	100K	100K	100K	100K	100K	100K
Retained Earnings	-651.54M	-680.42M	-707.25M	-683.61M	-672M	-666.3M	-649.5M	-584.3M	-378M	40.3M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-654K	-726K	-493K	-2.9M	-1.2M	5.5M	-2.2M	20M	8M	-13.2M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.55M	15.91M	41.3M	35.9M	98.4M	84M	-68.1M	119M	145.7M	430.3M
Operating CF Margin %	-0.05%	0.04%	0.09%	0.06%	0.13%	0.09%	-0.06%	0.09%	0.09%	0.21%
Operating CF Growth %	-2.41%	2.27%	1.6%	-0.13%	1.74%	-0.15%	-1.81%	2.75%	0.22%	1.95%
Net Income	-73.52M	-28.88M	-26.8M	3.3M	11.6M	6.8M	16.8M	4.6M	206.3M	418.3M
Depreciation & Amortization	15.84M	13.83M	13.9M	15.6M	27.9M	55.4M	57.4M	63.2M	72.8M	80.8M
Stock-Based Compensation	19.18M	23.62M	31.9M	37.5M	28.7M	35.9M	34.4M	40.9M	48.3M	69.3M
Deferred Taxes	0	0	0	0	0	0	0	-1M	500K	-136.9M
Other Non-Cash Items	17.95M	20.92M	20.6M	32.3M	49.9M	49.3M	86.9M	13.8M	8.4M	15.8M
Working Capital Changes	8M	-13.58M	1.7M	-52.8M	-19.7M	-63.4M	-263.6M	-2.5M	-190.6M	-17M
Change in Receivables	-9.79M	12.55M	-26.3M	-14.6M	-10.9M	-13.7M	-71.3M	-51.8M	-154.2M	-10.4M
Change in Inventory	-722K	-24.1M	1.7M	-38.8M	-30.2M	-50.5M	-154.4M	-49.1M	-53.6M	-32.4M
Change in Payables	17.99M	639K	27.3M	-5.4M	25.6M	7.1M	-15.6M	-2.4M	-11M	2.2M
Cash from Investing+	-15.32M	-178.01M	-210.8M	-184.5M	-73.6M	14M	-82.7M	-191.1M	-119.4M	-146.2M
Capital Expenditures	-10.61M	-22.11M	-77.23M	-162.35M	0	-166.5M	-122.7M	-157.3M	-109.2M	-134M
CapEx % of Revenue	0.04%	0.06%	0.17%	0.29%	0.23%	0.18%	0.11%	0.12%	0.06%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	26K	-46K	-170.9M	0	0	0	0	0
Cash from Financing+	-371K	176.57M	304.5M	-8.7M	73.5M	605.5M	40.7M	-40.3M	-13.6M	-28.1M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.65M	-2.87M	-4.1M	-17.82M	-8.6M	-30.3M	-32.2M	-16.8M	-13.5M	-7.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.16M	-6.2M	-36.02M	-126.45M	-72.5M	-82.5M	-190.8M	-38.3M	70.1M	305.4M
FCF Margin %	-0.09%	-0.02%	-0.08%	-0.22%	-0.1%	-0.09%	-0.17%	-0.03%	0.04%	0.15%
FCF Growth %	-8.03%	0.73%	-4.81%	-2.51%	0.43%	-0.14%	-1.31%	0.8%	2.83%	3.36%
FCF per Share	-0.41	-0.11	-0.62	-2.07	-1.16	-1.25	-2.78	-0.55	0.95	4.13
FCF Conversion (FCF/Net Income)	0.17x	-0.55x	-1.54x	10.91x	8.48x	12.35x	-4.05x	25.87x	0.71x	1.03x
Interest Paid	4.03M	3.69M	2.5M	0	0	2.6M	21.5M	34.2M	49.9M	0
Taxes Paid	109K	932K	500K	800K	2.5M	3M	7M	5.5M	8.1M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-124.74%	-59.42%	-24.21%	1.78%	8.06%	2%	2.9%	0.89%	34.12%	43.03%
Return on Invested Capital (ROIC)	-37.27%	-4.62%	-1.56%	3.6%	5.11%	4.98%	10.36%	2.41%	11.72%	14.43%
Gross Margin	50.5%	57.52%	59.76%	65.65%	65.06%	64.39%	68.45%	61.72%	68.35%	69.79%
Net Margin	-27.86%	-7.87%	-5.79%	0.58%	1.57%	0.75%	1.53%	0.35%	12.16%	20.19%
Debt / Equity	5.21x	5.27x	3.57x	2.79x	11.94x	1.78x	2.31x	3.01x	1.98x	1.17x
Interest Coverage	-3.83x	-0.74x	-0.39x	1.23x	1.45x	1.07x	2.04x	1.04x	6.08x	7.23x
FCF Conversion	0.17x	-0.55x	-1.54x	10.91x	8.48x	12.35x	-4.05x	25.87x	0.71x	1.03x
Revenue Growth	-8.6%	39.07%	26.37%	21.57%	30.93%	22.51%	21.49%	18.79%	30.02%	22.07%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
International Omnipod	301.67M	391.55M	-	673.5M	834.9M	1.01B	1.25B	1.66B	2.03B
International Omnipod Growth	-	29.79%	-	-	23.96%	21.14%	23.37%	33.12%	22.37%
Drug Delivery	65.31M	72.22M	-	64.7M	69.5M	87.4M	57.5M	36M	38.9M
Drug Delivery Growth	-	10.57%	-	-	7.42%	25.76%	-34.21%	-37.39%	8.06%

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	295.1M	343.81M	391.8M	485.1M	596.4M	738.9M	942.3M	1.29B	1.55B
UNITED STATES Growth	-	16.51%	13.96%	23.81%	22.94%	23.89%	27.53%	36.58%	20.30%
Non-US	71.89M	119.95M	172.02M	253.1M	308M	359.9M	363M	410.1M	523.4M
Non-US Growth	-	66.86%	43.41%	47.13%	21.69%	16.85%	0.86%	12.98%	27.63%

Frequently Asked Questions

Valuation & Price

Insulet Corporation (PODD) has a price-to-earnings (P/E) ratio of 49.6x. This suggests investors expect higher future growth.

Growth & Financials

Insulet Corporation (PODD) reported $2.52B in revenue for fiscal year 2024. This represents a 1556% increase from $152.3M in 2011.

Insulet Corporation (PODD) grew revenue by 22.1% over the past year. This is strong growth.

Yes, Insulet Corporation (PODD) is profitable, generating $246.2M in net income for fiscal year 2024 (20.2% net margin).

Dividend & Returns

Insulet Corporation (PODD) has a return on equity (ROE) of 43.0%. This is excellent, indicating efficient use of shareholder capital.

Insulet Corporation (PODD) generated $421.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.